OBJECTIVES: To assess the safety and acceptability of 2 vaginal microbicide gels (Acidform and BufferGel) used with a diaphragm compared to KY Jelly used with a diaphragm among low-risk, sexually abstinent women. STUDY DESIGN:Eighty-one women enrolled in a randomized, masked, phase I safety study using a diaphragm with Acidform, BufferGel, or KY Jelly for 6 to 10 hours nightly for 14 nights. Physical examination, colposcopy, and lab studies were performed after 1 and 2 weeks of use. Diaries and questionnaires were used to assess user acceptability. RESULTS:Sixty-nine participants (85%) completed the study. Safety and acceptability appeared similar among the 3 study groups and no serious adverse events related to the study products were reported. Adverse events were mild and anticipated. CONCLUSIONS:Acidform and BufferGel compared to KY Jelly, when used with diaphragm daily for 14 days, appeared to be safe and acceptable in a small study of low-risk abstinent women.
RCT Entities:
OBJECTIVES: To assess the safety and acceptability of 2 vaginal microbicide gels (Acidform and BufferGel) used with a diaphragm compared to KY Jelly used with a diaphragm among low-risk, sexually abstinent women. STUDY DESIGN: Eighty-one women enrolled in a randomized, masked, phase I safety study using a diaphragm with Acidform, BufferGel, or KY Jelly for 6 to 10 hours nightly for 14 nights. Physical examination, colposcopy, and lab studies were performed after 1 and 2 weeks of use. Diaries and questionnaires were used to assess user acceptability. RESULTS: Sixty-nine participants (85%) completed the study. Safety and acceptability appeared similar among the 3 study groups and no serious adverse events related to the study products were reported. Adverse events were mild and anticipated. CONCLUSIONS: Acidform and BufferGel compared to KY Jelly, when used with diaphragm daily for 14 days, appeared to be safe and acceptable in a small study of low-risk abstinent women.
Authors: Lindsay F Kramzer; Jessica Cohen; Jesse Schubert; Charlene S Dezzutti; Bernard J Moncla; David Friend; Lisa C Rohan Journal: Contraception Date: 2015-05-19 Impact factor: 3.375
Authors: Sara Pentlicky; Mark Rosen; Patricia S Coffey; M Kilbourne-Brook; A Shaunik; Courtney A Schreiber; Kurt Barnhart Journal: Contraception Date: 2012-08-13 Impact factor: 3.375
Authors: Kathleen L Vincent; Nigel Bourne; Brent A Bell; Gracie Vargas; Alai Tan; Daniel Cowan; Lawrence R Stanberry; Susan L Rosenthal; Massoud Motamedi Journal: Sex Transm Dis Date: 2009-05 Impact factor: 2.830
Authors: Deborah J Anderson; D'Nyce L Williams; Susan A Ballagh; Kurt Barnhart; Mitchell D Creinin; Daniel R Newman; Frederick P Bowman; Joseph A Politch; Ann C Duerr; Denise J Jamieson Journal: Am J Reprod Immunol Date: 2009-02 Impact factor: 3.886
Authors: Frieda M Behets; Abigail Norris Turner; Kathleen Van Damme; Ny Lovaniaina Rabenja; Noro Ravelomanana; Teresa A Swezey; April J Bell; Daniel R Newman; D'Nyce L Williams; Denise J Jamieson Journal: Sex Transm Dis Date: 2008-09 Impact factor: 2.830
Authors: Russell J Mumper; Michael A Bell; David R Worthen; Richard A Cone; Gareth R Lewis; Jeremy R A Paull; Thomas R Moench Journal: Drug Dev Ind Pharm Date: 2009-05 Impact factor: 3.225
Authors: Charlene S Dezzutti; Elizabeth R Brown; Bernard Moncla; Julie Russo; Marilyn Cost; Lin Wang; Kevin Uranker; Ratiya P Kunjara Na Ayudhya; Kara Pryke; Jim Pickett; Marc-André Leblanc; Lisa C Rohan Journal: PLoS One Date: 2012-11-07 Impact factor: 3.240